Fluorouracil + Irinotecan + Irinotecan Hydrochloride + Leucovorin + Leucovorin Calcium + Nivolumab + Oxaliplatin

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Borderline Resectable Pancreatic Adenocarcinoma

Conditions

Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma

Trial Timeline

Jul 24, 2019 → May 25, 2024

NCT ID

NCT03970252

About Fluorouracil + Irinotecan + Irinotecan Hydrochloride + Leucovorin + Leucovorin Calcium + Nivolumab + Oxaliplatin

Fluorouracil + Irinotecan + Irinotecan Hydrochloride + Leucovorin + Leucovorin Calcium + Nivolumab + Oxaliplatin is a phase 1 stage product being developed by Bristol Myers Squibb for Borderline Resectable Pancreatic Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03970252. Target conditions include Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma.

What happened to similar drugs?

0 of 4 similar drugs in Borderline Resectable Pancreatic Adenocarcinoma were approved

Approved (0) Terminated (0) Active (4)

🔄Olanzapine + placeboEli LillyPhase 3

🔄OlanzapineEli LillyPhase 3

🔄quetiapine extended-release + PlaceboAstraZenecaPhase 3

🔄Quetiapine FumarateAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03970252	Phase 1	Completed	Jul 24, 2019	May 25, 2024	Borderline Resectable Pancreatic Adenocarcinoma

Competing Products

12 competing products in Borderline Resectable Pancreatic Adenocarcinoma

See all competitors

Product	Company	Stage	Hype Score
Olanzapine + placebo	Eli Lilly	Phase 3	40
olanzapine	Eli Lilly	Pre-clinical	26
Olanzapine	Eli Lilly	Phase 3	40
Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab + Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate	Jiangsu Hengrui Medicine	Phase 2	31
Durvalumab + Tremelimumab + Gemcitabine + Cisplatin	AstraZeneca	Phase 2	27
quetiapine extended-release + Placebo	AstraZeneca	Phase 3	40
Quetiapine fumarate + Placebo	AstraZeneca	Phase 2	35
Quetiapine Fumarate	AstraZeneca	Phase 3	40
ziprasidone + Placebo	Pfizer	Phase 2	35
PD-1/PD-L1 inhibitors + Chemotherapy	BeOne Medicines	Phase 2	36
Fluorouracil + Irinotecan + Leucovorin + Leucovorin Calcium + Oxaliplatin + Quemliclustat + Zimberelimab	Arcus Biosciences	Phase 1/2	33
vafidemstat + Placebo	Oryzon Genomics	Phase 2	25